NASDAQ · EXEL
Exelixis, Inc.
$66.20-$0.08 (-0.12%)
Exelixis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
Loading market information…
NASDAQ · RIGL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Rigel Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.51% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Rigel Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of $0.92. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Rigel Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | $0.63+350.0% vs estimate | $53.33M+10.38% vs estimate |
|---|
| Q4 2024 | Mar 4, 2025 | $0.80+166.67% vs estimate | $57.60M+0.01% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.70+1,066.67% vs estimate | $55.31M+16.63% vs estimate |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $67.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$66.20-$0.08 (-0.12%)
Exelixis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$15.45-$0.11 (-0.71%)
Cullinan Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.38% below the high.
$9.66-$0.18 (-1.78%)
Verastem, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.72% below the high.
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
$3.30-$0.10 (-2.8%)
C4 Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.17% below the high.
$1.22+$0.04 (+3.39%)
ALX Oncology Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.14% below the high.
$0.91+$0.01 (+1.6%)
Cardiff Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.45% below the high.
